As per the press release issued by sanofi-aventis earlier today, Marc Cluzel, M.D., PhD, Executive Vice President, Research & Development, sanofi-aventis, said: "The results of this study show that lixisenatide once-daily in combination with basal insulin provides a significant reduction in A1C. Adding lixisenatide, a new GLP-1 with a strong post-prandial glucose effect, to a basal insulin may offer patients a new treatment approach to better control glucose and prevent long-term complications."

Positive study findings from the first GETGOAL MONO study with lixisenatide were presented on 20 September 2010 by sanofi-aventis at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting in Stockholm, Sweden. The results showed that lixisenatide, when dosed once-daily as a monotherapy, had a significant effect on postprandial blood glucose control and A1C levels with mean decreases in body weight observed in all dose groups.

The GETGOAL Phase III clinical trial program encompasses multiple clinical trials and will assess the efficacy and safety of lixisenatide in adult patients with Type-2 Diabetes mellitus treated with various oral antidiabetic agents or insulin. The GETGOAL program started in May 2008 and enrolled more than 4,000 patients at the time that enrollment was completed at the end of 2009. The next results of the GETGOAL program are expected to be released in Q2 2011.

SOURCE Zealand Pharma A/S